Arcadia Stockholders Approve Reverse Split and New Equity Plan

summarizeSummary

Arcadia Biosciences stockholders approved a reverse stock split (1-for-2 to 1-for-10, Board discretion until June 30, 2027) and a new 2026 equity incentive plan at the September 10 annual meeting.

check_boxKey Events · Corporate Governance and Compliance · RKDA

• Reverse Stock Split Approved

  Stockholders approved a reverse split at a ratio between 1-for-2 and 1-for-10, with the Board authorized to determine the exact ratio and timing before June 30, 2027. This is the company's primary mechanism to cure its Nasdaq bid price deficiency.

• New Equity Incentive Plan Approved

  The 2026 Omnibus Equity Incentive Plan was approved with an initial reserve of 400,000 shares, plus annual increases of up to 4% of outstanding shares beginning January 1, 2027.

• Series A-1 Preferred Option Share Issuance Approved

  Stockholders approved the potential issuance of common stock upon exercise of Series A-1 Preferred Investment Options issued in the June 12, 2026 private placement.

• Director Elected and Auditor Ratified

  Gregory D. Waller was elected as a Class II director, and Ramirez Jimenez International CPAs was ratified as independent auditor for the year ending December 31, 2026.

auto_awesomeAnalysis · RKDA · Energy & Transportation

Arcadia Biosciences stockholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-10, giving the Board discretion to execute it before June 30, 2027. This is the company's primary tool to cure its Nasdaq bid price deficiency after receiving two delisting notices. Stockholders also approved a new 2026 Omnibus Equity Incentive Plan with a 400,000-share initial reserve and the potential issuance of shares upon exercise of Series A-1 Preferred Investment Options from the June 2026 private placement. The reverse split approval is the critical step toward regaining Nasdaq compliance, but it does not by itself cure the deficiency — the Board must still decide the ratio and timing.